Alvogen, Inc. Initiates Nationwide Class II Recall of Levothyroxine Sodium Tablets Due to Product Mix-Up
Alvogen, Inc. has initiated a Class II nationwide recall (D-0259-2026) for Levothyroxine Sodium Tablets, USP, 150mcg, due to a critical product mix-up. A bottle from lot # MHA21825 was found to contain 88 mcg tablets instead of the labeled 150 mcg. This event signals significant supply chain and regulatory risks for procurement, regulatory affairs, and supply chain VPs.
FDA Mandates Class II Recall for Alvogen's Levothyroxine Sodium Due to Critical Product Mix-Up
Alvogen, Inc. has initiated a voluntary, firm-initiated Class II recall, designated D-0259-2026, for specific lots of its Levothyroxine Sodium Tablets, USP, 150mcg. This critical action stems from a reported product mix-up where a single bottle from lot # MHA21825 was found by a pharmacy to contain 88 mcg tablets instead of the labeled 150 mcg strength. The recall, initiated on December 31, 2025, is ongoing and affects distribution nationwide across the United States. For procurement directors, this means an immediate disruption to the supply of a vital thyroid hormone replacement medication. Regulatory affairs heads must assess the implications of a Class II classification, which indicates that the use of or exposure to the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. Supply chain VPs need to understand that this is not merely a labeling error but a fundamental failure in quality control, potentially leading to incorrect patient dosing and significant health risks. Business development executives should note the reputational damage and potential for market share shifts as customers seek more reliable suppliers for Levothyroxine Sodium.
Manufacturing and Distribution Network for Recalled Levothyroxine Sodium Tablets
The recalled Levothyroxine Sodium Tablets, USP, marketed under the brand name Thyro-Tabs, are manufactured by LLOYD, Inc. located in Shenandoah, IA 51601 USA, and distributed by Alvogen, Inc., with its primary address in Morristown, NJ 07960-4558. The specific product involved is the 150mcg strength, packaged as 1000 tablets, with NDC 47781-662-10, and an expiration date of December 31, 2027. This dual-entity involvement highlights a complex supply chain where a distributor like Alvogen relies on external manufacturers. For procurement directors, this necessitates a comprehensive review of supplier qualification processes, not just for the primary distributor but also for their contract manufacturers. Understanding the manufacturing site's quality control history and audit results is paramount. Supply chain VPs must map these relationships to identify all potential points of failure. The nationwide distribution pattern means that the impact of this product mix-up is widespread, affecting pharmacies and healthcare providers across the entire U.S. This event underscores the need for robust oversight mechanisms for all partners within the pharmaceutical supply chain, ensuring that quality standards are consistently met from production to patient delivery.
Supply Chain Exposure: Mitigating Risks for Levothyroxine Sodium Availability
The Class II recall of Alvogen's Levothyroxine Sodium Tablets, USP, presents a significant supply chain exposure risk, particularly given the critical nature of this medication for thyroid hormone replacement. Levothyroxine Sodium is a widely prescribed drug, and any disruption can have immediate consequences for patient care. The identified product mix-up, where 88 mcg tablets were found in a 150 mcg bottle, could lead to either under-dosing or over-dosing, both of which can have serious health implications for patients. For supply chain VPs, the immediate priority is to quantify the affected inventory within their distribution networks and assess the potential for stockouts. Procurement directors must initiate rapid communication with Alvogen, Inc. to understand the full scope of the recall and the availability of unaffected lots or alternative strengths. This incident serves as a stark reminder that even a single reported error can trigger a nationwide recall, demonstrating the fragility of just-in-time inventory systems for critical pharmaceuticals. Business development executives should anticipate increased demand for alternative Levothyroxine Sodium products from other manufacturers as pharmacies and healthcare systems seek to secure their supply.
Strategic Sourcing: Identifying Alternative Levothyroxine Sodium Suppliers
Given the ongoing Class II recall of Alvogen's Levothyroxine Sodium Tablets, USP, procurement directors must immediately activate their contingency plans for sourcing this essential medication. While the ChemLifeIntel Knowledge Graph does not specify alternative suppliers for Levothyroxine Sodium, the market for this widely used drug typically includes multiple manufacturers. Companies should review their existing qualified vendor lists to identify alternative sources for both the active pharmaceutical ingredient (API) and finished dosage forms. Key considerations include the alternative supplier's regulatory compliance history, manufacturing capacity, lead times, and the ability to meet specific dosage requirements (e.g., 150mcg, 88mcg). Supply chain VPs should prioritize suppliers with robust quality systems and a proven track record of FDA compliance to minimize future risks. Diversifying the supplier base across different geographies can also mitigate risks associated with localized regulatory actions or manufacturing disruptions. The qualification timeline for new pharmaceutical suppliers can be extensive, emphasizing the need for proactive identification and pre-qualification of multiple sources before a recall event occurs. This incident underscores the commercial imperative of a resilient, multi-source procurement strategy for critical drug products.
Heightened Regulatory Scrutiny and Alvogen's Path Forward Post-Recall
The Class II recall of Levothyroxine Sodium Tablets places Alvogen, Inc. under heightened regulatory scrutiny from the FDA. While the ChemLifeIntel Knowledge Graph does not indicate a history of prior Warning Letters or 483 observations specifically for Alvogen, this current recall event will undoubtedly trigger increased oversight. The 'Ongoing' status of the recall (D-0259-2026) means that the FDA is actively monitoring Alvogen's corrective and preventive actions (CAPA) to address the root cause of the product mix-up. Regulatory affairs heads at Alvogen and its manufacturing partner, LLOYD, Inc., must conduct a thorough investigation to determine how 88 mcg tablets were packaged into a 150 mcg bottle. This includes reviewing batch records, packaging line controls, and quality assurance protocols. Failure to implement effective CAPA could lead to further enforcement actions, including potential Warning Letters, import alerts, or even consent decrees. For business development executives, this means that Alvogen's reputation as a reliable supplier will be under review, potentially impacting future contracts and partnerships. Procurement teams should factor this increased regulatory risk into their supplier evaluations, demanding transparent communication on remediation efforts and evidence of sustained compliance.
Remediation Timeline and Commercial Repercussions for Alvogen's Market Position
Alvogen, Inc.'s voluntary recall, initiated on December 31, 2025, is currently in an 'Ongoing' status, indicating that the firm is actively managing the recall process and implementing necessary corrective actions. The immediate remediation steps involve identifying all affected product within the distribution chain, notifying customers, and facilitating returns. Beyond this, Alvogen and its manufacturing partner, LLOYD, Inc., are obligated to perform a comprehensive root cause analysis for the product mix-up involving Levothyroxine Sodium Tablets. This analysis must pinpoint the exact failure points in their manufacturing and quality control processes that allowed 88 mcg tablets to be packaged as 150 mcg. The subsequent implementation of robust Corrective and Preventive Actions (CAPA) will be crucial for regaining FDA confidence and restoring market trust. For supply chain VPs, monitoring the efficacy and speed of Alvogen's remediation is essential for forecasting future supply stability. Business development executives should evaluate the commercial repercussions, as competitors may capitalize on Alvogen's temporary supply disruption or reputational challenge. This event could lead to a shift in market share for Levothyroxine Sodium, impacting Alvogen's long-term position in the competitive generics market.